Navigation Links
Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
Date:9/11/2007

Deerfield, IL, September 11, 2007 Takeda Pharmaceuticals North America, Inc. is aware of the review of ACTOS (pioglitazone HCl) data conducted by A. Michael Lincoff, M.D., and colleagues at the Cleveland Clinic, published in the Journal of the American Medical Association which concluded that ACTOS is associated with a significantly lower risk of heart attack, stroke, or death among a diverse population of 16,390 patients with diabetes versus control therapy.

This new meta-analysis is consistent with the depth and breadth of ACTOS cardiovascular data: ACTOS studies, conducted over the past 10 years, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

Meta-analyses are pooled data across a number of studies. Although not definitive, they can offer insight into aspects of a compound or product that may not be readily available from individual studies. The overall effect calculated from a group of like or similar randomized trials can provide an estimate of the drugs overall effects in an expanded population.

This meta-analysis adds important information to the body of evidence regarding ACTOS and macrovascular ischemic events, and further documents the consistency of data from prospective studies, to meta-analysis, to observational studies.

Critical in this body of data is PROactive (PROspective PioglitAzone Clinical Trial In MacroVascular Events), a trial of patients with type 2 diabetes who are at high risk for cardiovascular events. Results from this prospective, randomized, placebo-controlled outcomes trial - considered by scientists to be the most scientifically rigorous type of study - were reviewed by the FDA and added to the ACTOS label. These data show no increase in mortality or total macrovascular events with ACTOS. ACTOS is the only thiazolidinedione (TZD) with safety data from a cardiovascular outcomes trial in its label.

Given the strength and consistency of the ACTOS data as demonstrated by the prospective studies, meta-analysis, and observational studies, Takeda remains confident in the ACTOS safety profile regarding the risk of macrovascular ischemic events.


'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
646-935-3917
Ketchum
Source:Eurekalert

Related medicine news :

1. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
2. Substituting soymilk for lactose intolerant students n schools: a great option
3. ACTOS Linked to Several Cardiovascular Benefits
4. Lactose-Intolerant kids need to take dairy products to meet nutrient requirements
5. Actos Linked To Bone Fractures In Diabetic Women
6. Largest Ever Study of Genetics Behind Common Diseases Published
7. A Just Published Book Promises To Guide Women Regarding Their Frequent UTI’
8. Findings on Dangerous Parasite, Toxoplasma Gondii Published
9. Siddha Medicine Texts to Be Published in English
10. Journal Recommends How To Improve The Performance Of Health Workers
11. Medical Journals should create awareness on Child survival
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Discover the Rocky Mountain region’s longest running ... 700 companies. Attendees also get to see the most incredible gardens and home ... Show , at the Colorado Convention Center - 700 14th St. Denver CO, is ...
(Date:2/8/2016)... KS (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com ... leader in Mole removal products. , Moles are derived from a cluster of melanin ... in all the wrong places and create a lifetime of embarrassment. Historically, mole ...
(Date:2/8/2016)... ... , ... The schedule is now online for the largest and ... is being held May 25-29 at the Loews Chicago O’Hare Hotel, continues to give ... of chronic illness in children. , Very recent articles have cited 1 child in ...
(Date:2/7/2016)... , ... February 07, 2016 , ... Women's Excellence staff, ... Wear Red Day. National Wear Red Day is the first Friday each February ... disease and stroke cause 1 in 3 deaths among women each year – more ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT: ... world with an estimated 5000 perioperative nurses in attendance to study the ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... FOSTER CITY, Calif., Feb. 8, 2016  Aoxing Pharmaceutical Company, Inc. ... of fiscal year 2016, ended December 31, 2015, the Company ... $6,430,701 recorded in the same quarter in fiscal 2015. ... income in Q2 of fiscal year 2016 was $2,068,635, or ... $567,169, or $.01 per share, in the Q2 of fiscal ...
(Date:2/8/2016)... ORLANDO, Fla. , Feb. 8, 2016 ... and marketing high performance apparel for healthcare and other ... Bold Chief Executive Officer. He replaces Dale ... and remains Chairman. Mr. Bold is also joining Vestagen,s ... in a new class of active barrier technologies that ...
(Date:2/8/2016)... Utah , Feb. 8, 2016  Dynatronics ... distributor of advanced-technology medical devices and rehabilitation equipment ... markets, congratulates the Denver Broncos, football team for ... H. Cullimore Jr. , Chairman and Chief Executive ... excellence and we look forward to enhancing their ...
Breaking Medicine Technology: